Product Information
VYZULTA 0.024% OPHTH SOLUTION is a brand product labeled by Bausch & Lomb Incorporated, priced at $102.2899 per ML under NDC 24208050402. Its NADAC has been published 402 times since Jan 23, 2019.
FDA first approved this application on Nov 2, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.24 mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208050402
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
LATANOPROSTENE BUNODApproval Type
New Drug (NDA)
FDA Application
NDA207795FDA Approved
11/2/2017
TE Code
AB
On Market Since
11/2/2017
Price Statistics
The NADAC for VYZULTA 0.024% OPHTH SOLUTION has been published 402 times since Jan 23, 2019, and over the history we have for it it has risen 48.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $102.2899 per ML |
|---|---|
| All-time high | $102.4567 (May 13, 2026) |
| All-time low | $68.9624 (Jan 23, 2019) |
| 52-week high | $102.4567 |
| 52-week low | $99.4365 |
| Median price | $87.4633 |
| Average price | $88.7169 |
| Largest weekly change | +6.0% (Jan 12, 2022) |
| Weeks tracked | 402 |
| Tracking since | Jan 23, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
latanoprostene bunod market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VYZULTA 0.024% OPHTH SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for VYZULTA 0.024% OPHTH SOLUTION, manufactured by Bausch & Lomb Incorporated, is $102.2899 per ML (NDC 24208050402), effective Sep 30, 2026.
How has the price of VYZULTA 0.024% OPHTH SOLUTION changed over time?
Over the history we have for it, the NADAC for VYZULTA 0.024% OPHTH SOLUTION has risen 48.3%. It has been tracked across 402 weekly CMS publications since Jan 23, 2019.
What are the highest and lowest recorded NADAC prices for VYZULTA 0.024% OPHTH SOLUTION?
Since Jan 23, 2019, the NADAC for VYZULTA 0.024% OPHTH SOLUTION has ranged from a low of $68.9624 (Jan 23, 2019) to a high of $102.4567 (May 13, 2026), with a median of $87.4633 per ML.
Are there cheaper alternatives to VYZULTA 0.024% OPHTH SOLUTION?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VYZULTA 0.024% OPHTH SOLUTION, is $102.2513 per ML — about 0% below VYZULTA 0.024% OPHTH SOLUTION.
Who manufactures VYZULTA 0.024% OPHTH SOLUTION?
VYZULTA 0.024% OPHTH SOLUTION (NDC 24208050402) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.